PD1-CD19-CART in Patients With r/r B-cell Lymphoma
NCT04213469
·
clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
20
Enrollment
INDUSTRY
Sponsor class
Conditions
B-cell Lymphoma
Interventions
BIOLOGICAL:
PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells
Sponsor
Bioray Laboratories
Collaborators
[object Object]